Chimeric Antigen Receptor (CAR-T) Cell Therapy – Market Opportunity, Pipeline & Competitive Intelligence 2020$2,400.00 – $7,200.00Chimeric antigen receptor (CAR) T-cell therapy has generated a great amount of interest and have encouraged investors to support development in the field of adoptive cellular immunotherapy. Over the past couple of years, there has been rapid progress in the field. Researchers are refining the safety and efficacy profiles of CAR T cells with new concepts and technologies. These will be therapies that will address current challenges through mechanisms of superior efficacy, safety and delivery.
T-Cell Receptor (TCR) Therapy- Executive Report 2020$3,000.00 – $9,000.00
A Comprehensive Review on TCR Cell Therapy by Pipeline Analysis, Emerging Players having Innovative Portfolio, Commercial Assessment of Developmental Activities, Therapeutic Portfolio Assessment, Objective Assessment of Unmet Needs, Future Perspectives, and Technological Advancements to make informed R&D related decisions, modify therapeutic portfolio strategies, identify growth opportunities, strengthen or expand business by gaining extensive view.